We have identified a single nucleotide polymorphism in the 5Ј region of the human interleukin-1 receptor type I (IL-1RI) gene, a C → A transversion at position 52 in exon 1C (GenBank accession number AF172151) which creates a Bsr BI restriction endonuclease site. Allele frequencies in a Caucasian population were 0.72 (C allele) and 0.28 (A allele). Genes and Immunity (2000) 1, 234-235.
The human interleukin-1 type I receptor (IL-1RI) is the signal transducing receptor for IL-1, a principal proinflammatory cytokine. The IL-1RI gene is alternatively transcribed from three different exons within the 5Ј-untranslated region: exons 1A, 1B and 1C. 1, 2 This region has been shown to be polymorphic, and to date five sin- gle nucleotide polymorphisms have been described: two in intron 1A;
3 one in exon 1B; 3 one in intron 1B; 4 and one in exon 1C. 4 Here, we report a further single nucleotide polymorphism C → A in exon 1C at position 52 relative to the start of the exon 1 ( Figure 1 ). The polymorphism was detected using polymerase chain reaction amplification and single-stranded conformational polymorphism (PCR-SSCP) analysis 5 ( Figure 2 ) and confirmed by nucleotide sequencing. The polymorphism creates a Bsr BI restriction endonuclease site, and Bsr BI restriction fragment length polymorphism (RFLP) analysis was used to determine allele frequencies in a population of 98 healthy Caucasian volunteer blood donors from the South We previously reported 4 an A → T transversion polymorphism in exon 1C of the IL-1RI gene at position 140, in which the allele frequencies were very similar to those for the C → A transversion at position 52 described in the present manuscript. We are currently investigating the extent of linkage between these two polymorphisms, and others previously reported. . PCR products (10 l) were digested in 20 l volumes containing Bsr BI (10 units) for 4 h at 37°C, according to conditions recommended by the supplier (New England Biolabs, Hitchin, Herts, UK). Restriction endonuclease fragments were resolved in 12% nondenaturing polyacrylamide gels (Accugel, National Diagnostics, Atlanta, GA, USA) at 300 V for 45 min, using the triple-wide minigel system described (Figure 2 legend) .
